Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Machine learning holds key to personalised cancer drugs
  • News

Machine learning holds key to personalised cancer drugs

  • 8 April 2021
  • Janet Fricker
Machine learning holds key to personalised cancer drugs
Total
0
Shares
0
0
0
0
0

Researchers have developed a machine learning (ML) algorithm that can be used to rank the effectiveness of different drugs in reducing cancer cell growth for individual patients. In Nature Communications (25 March 2021), the UK investigators report the feasibility of their new Drug Ranking Using Machine Learning (DRUML) technology, which predicted drug responses in independent verification data sets with low error. The new approach, they claim, offers the potential to be a game changer using predictive algorithms for truly personalised cancer treatments.

Biomarker testing and next-generation sequencing (NGS) are becoming more widely used in routine practice to identify genetic markers predicting patient response to targeted agents. However, the approach fails to take into consideration the complexity of the cancer biological landscape, where multiple biochemical pathways can compensate for each other. “The limitation of companion diagnostics is that they only measure the activity of one pathway at a time, and don’t tell you when there’s a compensatory pathway present,” explains Pedro Rodriguez Cutillas, who led the study. Compensatory mechanisms, he adds, explain why targeted therapies do not work in all cancer patients carrying mutations. In melanoma, for example, it is estimated BRAF inhibitors only work in around half of patients with BRAF mutations. “Machine learning can be used to overcome these issues by constructing algorithms that consider not just one molecular marker but several different markers, and can take into account the activity of the different pathways, allowing you to rank efficacy of different agents,” explains Cutillas, from Barts Cancer Institute (BCI), Queen Mary University of London, UK.

First, to build the DRUML model, Cutillas and his team used datasets derived from proteomics (the study of proteins in cells) and phosphoproteomics (the study of how these proteins are modified) using 26 acute myeloid leukaemia, 10 oesophagus and 12 hepatocellular cell lines. For the model they incorporated data on 8000 different proteins and 20,000 different phosphorylation sites from cell lines correlating with whether 412 different drugs (both chemotherapy and targeted agents) were found to be effective or resistant. “The significance of incorporating information on phosphorylation is phosphorylated proteins tend to be more active, helping the model identify the most active pathways that would benefit a particular patient most from being blocked,” explains Cutillas.

Having constructed the algorithm, the investigators were then able to input individual patient data containing information on baseline proteomics and phosphoproteomics, leading to an output of lists ranking the 412 drugs according to antiproliferative efficacy for a given patient.

The team obtained data for 53 different cancer cell models, that had been analysed by independent laboratories, which they fed into their DRUML model. Using the model, the predicted rankings were compared with the actual rankings found when samples were exposed to the 412 different drugs. Results showed 85 % of their predictions were within 15% error and the drug rankings were statistically significant (by Spearman) within all cancer models tested. “This represents a remarkable and surprising accuracy given that DRUML was trained using oesophageal and liver cancers, whereas the verification datasets consisted of data from cell lines derived from bone, brain, breast, cervix, colorectal, ovary and prostate cancers,” write the authors.

The team are currently in discussions with commercial partners to develop the technology further, and hope to undertake a clinical trial validating the approach. The trial, explains Cutillas, would involve comparing overall survival of patients matched to drugs using the algorithm with those matched using conventional methods. Taking DRUML technology a step further, adds Cutillas, it could be possible to incorporate data on surrounding non-cancerous cells from individual patients into the model. “This would provide insights on side effects and the drugs’ therapeutic windows (the difference between drugs’ ability to kill cancer cells relative to normal cells) that could be used to further help prioritise drugs for individual patients,” he explains.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • biomarker testing
  • machine learning
  • next-generation sequencing
  • personalised medicine
  • phosphoproteomics
  • proteomics
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Policy

Older, frail patients are still being let down by the regulators

  • 8 April 2021
  • Sophie Fessl
View Post
Next Article
  • Supported contents

What is efficiency in Latin America?

  • 9 April 2021
  • Adriana Albini
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
  • AI application in diagnosis
    • 11 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.